Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Sets New 1-Year High – Here’s Why

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) shares reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $8.29 and last traded at $7.96, with a volume of 150683 shares trading hands. The stock had previously closed at $7.78.

Shionogi & Co., Ltd. Stock Up 1.8 %

The company has a debt-to-equity ratio of 0.01, a current ratio of 7.64 and a quick ratio of 7.01. The business has a 50 day moving average of $7.55 and a 200 day moving average of $7.25. The firm has a market capitalization of $14.09 billion, a price-to-earnings ratio of 13.11, a price-to-earnings-growth ratio of 2.37 and a beta of 0.21.

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) last posted its quarterly earnings results on Friday, January 31st. The company reported $0.16 earnings per share (EPS) for the quarter. Shionogi & Co., Ltd. had a net margin of 35.53% and a return on equity of 12.02%. On average, equities analysts anticipate that Shionogi & Co., Ltd. will post 0.66 EPS for the current year.

Shionogi & Co., Ltd. Company Profile

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.